Atsushi Kimbara

This inventor holds 16 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 16 EPO patents. Top assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Atsushi Kimbara. Retrieved from https://idiyas.com/inventor/atsushi-kimbara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 56.3

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 86(Granted Patents)

Location History:

Tokyo, JP (2014 - 2016)
Shizuoka, JP (2015 - 2019)

Company Filing History:

14 out of 5,026

Hoffmann-La Roche Inc.

patents

2 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

Years Active: 2014-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441735 - Nitrogen-containing heterocyclic compound having NRF2 activation effect (2025-10-14),

2. 10308659 - Pyridine derivatives (2019-06-04),

3. 9694012 - Pyrazol derivatives (2017-07-04),

4. 9593123 - Triazolo[4,5-D]pyrimidine derivatives (2017-03-14),

5. 9580435 - Pyrrolo[2,3-D]pyrimidine derivatives as CB2 receptor agonists (2017-02-28),

6. 9522886 - Pyridine derivatives (2016-12-20),

7. 9512132 - Pyrazole compounds as CB2 agonists (2016-12-06),

8. 9505762 - Purine derivatives as CB2 receptor agonists (2016-11-29),

9. 9499553 - Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same (2016-11-22),

10. 9409866 - Pyridine-2-amides useful as CB2 agonists (2016-08-09),

11. 9321727 - Pyridine derivatives as agonists of the CB2 receptor (2016-04-26),

12. 9303012 - Pyridine-2-amides useful as CB2 agonists (2016-04-05),

13. 9090615 - Adamantyl derivatives as cannabinoid receptor 2 agonists (2015-07-28),

14. 9067943 - [1,2,3]triazolo[4,5-D]pyrimidine derivatives (2015-06-30),

15. 9056866 - [1,2,3]triazolo[4,5-D]pyrimidine derivatives (2015-06-16),

Title: Atsushi Kimbara: Innovator in Medicinal Chemistry

Introduction

Atsushi Kimbara is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of medicinal chemistry, holding a total of 16 patents. His work focuses on developing compounds that have therapeutic effects, particularly in activating important cellular pathways.

Latest Patents

Among his latest patents is a nitrogen-containing heterocyclic compound that exhibits an NRF2 activation effect. This invention provides a low-molecular compound or a salt thereof, which has the ability to activate Nrf2, a crucial protein in cellular defense mechanisms. The compound is represented by a specific formula, where various components are selected from groups including hydrogen, halogen, and C-Calkoxy. Another notable patent involves pyridine derivatives, which can be utilized as medicaments, showcasing his innovative approach to drug development.

Career Highlights

Atsushi Kimbara has worked with notable companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Chugai Seiyaku Kabushiki Kaisha. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in medicinal chemistry.

Collaborations

Throughout his career, Kimbara has collaborated with esteemed colleagues such as Uwe Grether and Mark Rogers-Evans. These partnerships have fostered an environment of innovation and have led to the development of impactful medicinal compounds.

Conclusion

Atsushi Kimbara's contributions to medicinal chemistry through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.